PolyPid Ltd.

PolyPid Ltd. is an innovative biopharmaceutical company headquartered in Petach Tikva, Israel. The company is dedicated to advancing long-acting, controlled-release medicines that deliver therapy precisely at the site of care, with a mission to improve patient outcomes by enhancing treatment effectiveness and addressing critical unmet medical needs across various therapeutic areas, including surgical care and metabolic diseases.

At the core of PolyPid's offerings is its proprietary Kynatrix™ (also known as PLEX) drug delivery platform, which enables the targeted, localized, and prolonged release of active pharmaceutical ingredients (APIs) over durations ranging from several days to months. The company's lead product candidate, D-PLEX100, is designed for the prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PolyPid's pipeline also includes a long-acting GLP-1 receptor agonist delivery platform (PP03A) for diabetes and weight management, and OncoPLEX (PP04A) for oncology, specifically targeting intratumoral cancer treatment, developed in collaboration with ImmunoGenesis.

Dikla Czaczkes Akselbrad serves as the Chief Executive Officer, having assumed the role effective July 1, 2022. In June 2026, PolyPid completed the New Drug Application (NDA) submission to the FDA for D-PLEX100, which has received Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations from the FDA. A potential FDA decision for D-PLEX100 is anticipated in the first quarter of 2027, following positive results from its Phase 3 SHIELD II trial, which demonstrated a 60% reduction in SSIs. The company further expanded its market positioning in July 2025 by unveiling a 60-day GLP-1 delivery platform, aiming to address the growing diabetes and weight management market.